Th e discovery that circulating anti-DNA antibodies are a diagnostic feature of patients with systemic lupus erythematosus helped defi ne the disease (reviewed by Foster et al. 1 ). Anti bodies against doublestranded DNA are relatively specifi c, and the presence of other auto antibodies (for example, anti-SmRNP) provides further diagnostic support. Initial correlation of serum autoantibody levels with disease activity in some patients led to the notion that these antibodies were pathogenic, and this was supported by the fi nding that high-affi nity, anti-DNA antibodies were present in the kidney eluates of lupus patients. However, it turned out that these and other correlations were inconsistent and of limited clinical utility in predicting either the type of nephritis or disease severity in individual patients. 2 In this regard, distinguishing pathogenic from non-pathogenic antibodies has been diffi cult, and interpretation is further muddled by diverse clinical manifestations among patients. Not only does organ involvement vary, but during the course of a person ' s lifetime, organs can be involved variably and diff erentially. 3 In one sense, the kidney represents a microcosm of systemic manifestations, with a varying spectrum of lesions involving glomeruli, larger vessels, and tubules. Furthermore, the spectrum of glomerular involvement is considerable, from only immune depo sits without pathologic or clinical evidence of disease, to crescentic glomerulonephritis, accompanied by severe interstitial and vascular infl ammation, with rapidly progressive renal failure. Nevertheless, in human lupus, the quantity and location of glomerular immune depo sits generally correlate with the class and severity of nephritis. 1, 3 Many factors contribute to pathogenesis; however, immune deposit formation is critical. Th erefore, what makes lupus autoantibodies form immune deposits is crucial to deciphering the disease process.
Keys to understanding autoantibody pathogenicity have been, in part, derived from analysis of inbred murine strains that spontaneously develop lupus. Some strains develop severe nephritis, whereas others do not. Comparison of serum antibodies among lupus strains, along with analysis of IgG eluted from the kidneys of nephritic mice, revealed that the eluted antibodies were more broadly reactive than the serum antibodies, in that they reacted and crossreacted with multiple autoantigens, including cell-surface, matrix, and basement membrane antigens. 1, 4 By contrast, serum autoantibodies were more restricted with specificity directed at DNA and nucleoproteins, and they were not crossreactive. Comparisons in human lupus provided similar fi ndings. 5 A partial explanation for this crossreactivity was that the seemingly diverse antigens shared epitopes, although induced fi t may also play a role. Although this does not explain autoantibodies with reactivity to glomerular antigens, per se, collectively the fi ndings suggest that antigen binding is relevant to pathogenesis in general, and immune deposit formation in particular.
Evaluation of the pathogenicity of monoclonal autoantibodies derived from lupusprone mice and lupus patients provided additional insights. Aft er injection into normal mice, some anti-DNA antibodies produced immune deposits and nephritis, whereas others did not. 6, 7 Th e pathogenic antibodies were typically IgG and more crossreactive, much like those eluted from the nephritic kidneys. It is particularly noteworthy that, among the pathogenic subset, the location of immune deposits formed varied with the individual antibodies. Strikingly, this was especially apparent when antibodies from diff erent laboratories were compared. For example, some formed predominantly subendothelial deposits, whereas others formed mesangial deposits, and others were more like cryoglobulins. Furthermore, independent analysis revealed that lupus autoantibodies that shared encoding V gene sequences, derived from diff erent mice and diff erent strains, produced similar pathologies. 8 -10 Moreover, autoantibodies derived from lupus-prone mice that were encoded by sequences similar to those encoding pathogenic anti-DNA antibodies, but that did not bind to DNA, bound to glomerular autoantigens (for example, laminin) and produced pathologies similar to those produced by
The relevance of antigen binding to the pathogenicity of lupus autoantibodies
Although lupus autoantibodies provide diagnostic value, discordance between serum levels and nephritis poses mechanistic questions. Krishnan and co-workers report that only those that crossreact with basement membrane components produce immune deposits. Thus, other glomerular binding properties probably define where deposits form. Thereafter, Fc-and complement-mediated events influence disease expression. Clearly other factors determine the ultimate phenotype; however, the findings provide insights into the variable disease patterns in lupus nephritis.
the nephritogenic anti-DNA antibodies. 1 Collectively the fi ndings suggested that specific antigen-binding properties of the autoantibodies mediated immune deposit formation by direct binding to glomerular antigens, and that these specifi cities infl uenced both the location of immune deposits formed and subsequent pathology ( Figure 1 ).
Other mechanisms of immune deposit formation have been proposed. 11, 12 In situ immune deposit formation of nucleosomes and autoantibodies has been suggested to occur by initial charge -charge interaction of positively charged nucleosomes with negatively charged constituents in the basement membrane (for example, heparan sulfate), with subsequent binding of either anti-DNA antibodies or anti-nucleosome antibodies to antigenic components within the exposed nucleosome (for example, DNA). Immune deposit formation in this manner seems feasible; however, overt nephritis by this mechanism has not been demonstrated.
Krishnan and co-workers 13 (this issue) further address the relevance of these in situ mechanisms by comparing the immune deposit-forming capacity of related anti-DNA antibodies, but with different relative affinities for basement membrane constituents. Th ey fi nd that only anti-DNA antibodies that bind to components of the basement membrane form immune deposits, activate complement, and induce proteinuria. Furthermore, they observe the presence of autoantibodies alone within the deposits, without other chromatin material, further supporting the direct binding mechanism. Th is is consistent with previous observations demonstrating pathogenicity of lupus autoantibodies via direct interactions with glomerular antigens. Th ey clearly defi ne this as a major mechanism of immune deposit formation in lupus nephritis.
However, this is probably the tip of the iceberg in terms of disease-relevant antigens in lupus nephritis. Seek, and ye shall fi nd. Many antigenic specifi cities for autoantibodies have been observed in individuals with lupus, and these specifi cities contribute to disease variability. Anti-DNA antibodies represent a signifi cant fraction of deposited immunoglobulins, but the larger fraction of immunoglobulins eluted from nephritic kidneys do not bind to DNA. 4, 5, 14 In this regard, we observed that monoclonal lupus autoantibodies with glomerular binding properties (for example, versus laminin) are encoded by genes encoding anti-DNA antibodies, suggesting that they have common origins. Importantly, the results indicate that other direct binding activities are relevant to pathogenesis. 15 Th e fi ndings also indicate that in a given person with lupus, the dominant autoantigen-binding profi le, at a given point in time, determines whether and where immune deposits will form. Th is probably explains the relative lack of correlation of either anti-DNA levels or circulating immune complex levels with disease activity. Th e phenomena also contribute to the diversity of lesions observed among patients.
Th e in situ mechanism involving socalled ' planted antigens ' in the kidney, with subsequent autoantibody binding, probably amplifi es disease, as with binding of anti-nucleosome antibodies to nucleosomes or of anti-IgG to deposited IgG (that is, by rheumatoid factors). In this context, antibody binding to fi xed glomerular antigens, in situ , provides an ideal scaff old for subsequent FcR engagement and local complement activation that is necessary for amplification of infl ammation. 16 Th e results of Krishnan et al. 13 clarify previous discrepancies. Local immune deposit formation has been observed to be critical for initiating nephritis in other experimental models and human disease. Preformed, circulating immune complexes do not appear to play a major role in this context. This conclusion is in accord with clinical observations that dissociate immune complex levels from disease severity. Furthermore, it is consistent with similar mechanisms in other antibody-dependent experimental autoimmune models and human nephritis, where disease is dependent on either local immune complex formation or antigen-specific cellular responses. In lupus, antigenic specifi city is essential, and direct binding of autoantibodies is key to pathogenesis. Th is principle helps explain variable organ involvement in lupus patients. Th us, although systemic lupus erythematosus is characterized by multiorgan involvement and the presence of circulating anti-DNA antibodies, the autoantigens that autoantibodies react with are crucial to where deposits form. Th is defi nes organ involvement in an individual patient. In the context of nephritis, the capacity of autoantibodies to bind to glomerular antigens determines and infl uences the quality and intensity of disease activity. In one sense, the kidney represents a microcosm of the organism, with variable disease depending on the antigenic specificity in a given lupus patient. Whereas anti-erythrocyte antibodies lead to hemolytic anemia, antineuronal antibodies produce cerebritis, and autoantibodies that react with renal antigens initiate nephritis of one type and / or another. Once immune deposits form, the capacity of the deposited antibodies to engage FcR and activate complement infl uences disease severity. Th ereaft er, other mechanisms may be operative in amplifying immune deposit formation, with loss of tolerance via neoantigen exposure, binding of anti-IgG, and so on. Nevertheless, the results of Krishnan and co-workers 13 provide conclusive evidence that the initial events are mediated by autoantibody binding to glomerular antigens. Th ey demonstrate this for anti-DNA antibodies. In this context it is likely that other autoantibodies / autoantigens are involved in the process. Although anti-DNA antibodies constitute a signifi cant fraction of deposited IgG, at most, they represent less than half of the deposited IgG. Individual observations of autoantibody binding to various renal antigens contribute, and these specifi cities infl uence the variable disease process. The particular specifi city that dominates in a given individual probably aff ects disease expression.
Is that all there is? Defi nitely not. Both B cells and T cells themselves actively participate in various stages of disease, and macrophages play a major role. Th e intensity of the infl ammatory and fi brogenic responses is crucial to severity, and this is determined by the autoimmune response, the systemic inflammatory response, and the kidney ' s response to the assault. Nevertheless, in addition to clarifying the major mechanism of immune deposit formation in lupus nephritis, the results of Krishnan and co-workers 13 raise questions pertaining to the functional consequences of antigen ligation, per se, during the disease process. Does ligation interfere with properties associated with fi ltration? With normal cell -cell interactions? With cell -matrix interactions? With normal repair processes and events? A more precise understanding of the participants and mechanisms involved in the disease process should lead to better means to monitor disease activity.
If confi rmed in human lupus, the results have implications for both biomarker development and therapy. More refi ned biomarkers using glomerular cell-surface antigens and glomerular matrix proteins have the potential to define when the kidney-specifi c, autoimmune response is active. Timing immunosuppressive therapy to this window in patients with nephritis would help defi ne when to initiate immunosuppressive therapy and when to limit its use. Th is would be especially helpful to improve reversibility, reduce fi brosis, and limit the toxic eff ects of immunosuppressive therapy. Additionally, strategies might be devised that either eliminate or silence these particular B cells, limit autoreactive B cell -T cell interactions, or prevent nephritogenic antibodies from depositing. Although targeting anti-DNA antibodies was not successful, targeting either kidneyspecific autoantibodies or the specific population of T cells that activate them has the potential to limit disease with less toxicity. Validation of the fi ndings in human lupus should be particularly helpful.
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